MCID: HML002
MIFTS: 63

Hemolytic Anemia

Categories: Blood diseases, Genetic diseases, Immune diseases, Metabolic diseases, Rare diseases

Aliases & Classifications for Hemolytic Anemia

MalaCards integrated aliases for Hemolytic Anemia:

Name: Hemolytic Anemia 12 29 6 15 37 62 17
Anemia, Hemolytic 43 39 71
Anemia Hemolytic 12 54

Classifications:



External Ids:

Disease Ontology 12 DOID:583
MeSH 43 D000743
NCIt 49 C34376
SNOMED-CT 67 61261009
ICD10 32 D55-D59
UMLS 71 C0002878

Summaries for Hemolytic Anemia

PubMed Health : 62 About hemolytic anemia: Hemolytic anemia (HEE-moh-lit-ick uh-NEE-me-uh) is a condition in which red blood cells are destroyed and removed from the bloodstream before their normal lifespan is over. Red blood cells are disc-shaped and look like doughnuts without holes in the center. These cells carry oxygen to your body. They also remove carbon dioxide (a waste product) from your body. Red blood cells are made in the bone marrow—a sponge-like tissue inside the bones. They live for about 120 days in the bloodstream and then die. White blood cells and platelets (PLATE-lets) also are made in the bone marrow. White blood cells help fight infections. Platelets stick together to seal small cuts or breaks on blood vessel walls and stop bleeding. When blood cells die, the body's bone marrow makes more blood cells to replace them. However, in hemolytic anemia, the bone marrow can't make red blood cells fast enough to meet the body's needs. Hemolytic anemia can lead to many health problems, such as fatigue (tiredness), pain, irregular heartbeats called arrhythmias (ah-RITH-me-ahs), an enlarged heart, and heart failure.

MalaCards based summary : Hemolytic Anemia, also known as anemia, hemolytic, is related to congenital hemolytic anemia and congenital nonspherocytic hemolytic anemia, and has symptoms including icterus An important gene associated with Hemolytic Anemia is SPTB (Spectrin Beta, Erythrocytic), and among its related pathways/superpathways are Metabolism and Glycosaminoglycan metabolism. The drugs Ribavirin and Peginterferon alfa-2a have been mentioned in the context of this disorder. Affiliated tissues include testes, liver and bone, and related phenotypes are Decreased viability and Decreased viability

Wikipedia : 74 Hemolytic anemia is a form of anemia due to hemolysis, the abnormal breakdown of red blood cells (RBCs),... more...

Related Diseases for Hemolytic Anemia

Diseases in the Hemolytic Anemia family:

Anemia, Autoimmune Hemolytic Congenital Hemolytic Anemia
Rare Acquired Hemolytic Anemia Hemolytic Anemia Due to Erythrocyte Adenosine Deaminase Overproduction
Hemolytic Anemia Due to an Erythrocyte Nucleotide Metabolism Disorder Hemolytic Anemia Due to a Disorder of Glycolytic Enzymes
Hemolytic Anemia Due to Hexose Monophosphate Shunt and Glutathione Metabolism Anomalies Rare Hemolytic Anemia

Diseases related to Hemolytic Anemia via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 1014)
# Related Disease Score Top Affiliating Genes
1 congenital hemolytic anemia 35.0 SPTB SPTA1 SLC4A1 PKLR PIEZO1 HBB
2 congenital nonspherocytic hemolytic anemia 34.9 PKLR PIEZO1 PGK1 NT5C3A HBB GPI
3 pyruvate kinase deficiency of red cells 34.8 PKLR PIEZO1 G6PD
4 rare hemolytic anemia 34.6 SPTB HBB
5 hereditary spherocytosis 34.4 SPTB SPTA1 SLC4A1 RHAG PKLR PIEZO1
6 glucosephosphate dehydrogenase deficiency 34.4 PKLR HBB G6PD
7 glutamate-cysteine ligase deficiency 34.2 SPTB SPTA1 SLC4A1 PIEZO1 GCLC
8 glutathione peroxidase deficiency 34.1 HBB HBA2
9 dehydrated hereditary stomatocytosis 1 with or without pseudohyperkalemia and/or perinatal edema 33.9 SLC4A1 PIEZO1 EPB42
10 erythrocytosis, familial, 8 33.9 HBB HBA2
11 pyropoikilocytosis, hereditary 33.6 SPTB SPTA1
12 thalassemia 33.5 SLC4A1 HBB HBA2 G6PD
13 glutathione synthetase deficiency 33.4 GSS G6PD
14 anemia, x-linked, with or without neutropenia and/or platelet abnormalities 33.4 HBB HBA2 G6PD
15 hereditary stomatocytosis 33.3 SLC4A1 RHAG PIEZO1
16 hereditary elliptocytosis 33.3 SPTB SPTA1 SLC4A1 RHAG PIEZO1 HBB
17 spherocytosis, type 2 32.8 SPTB SPTA1 HBB
18 hemoglobin zurich 32.7 HBB HBA2
19 hemoglobinopathy 31.9 HBB HBA2 G6PD
20 sickle cell disease 31.8 HBB HBA2 G6PD
21 beta-thalassemia 31.7 SPTB SLC4A1 HBB HBA2 G6PD
22 glucosephosphate isomerase deficiency 31.7 GPI G6PD
23 neonatal jaundice 31.7 SPTA1 PKLR G6PD ADAMTS13
24 iron metabolism disease 31.7 HBB HBA2 G6PD
25 sickle cell anemia 31.6 HBB HBA2 G6PD
26 splenic sequestration 31.5 HBB EPB42 ADAMTS13
27 malaria 31.4 SPTB SLC4A1 PKLR HBB HBA2 G6PD
28 hemochromatosis, type 1 31.4 PKLR PIEZO1 HBB HBA2
29 neonatal anemia 31.1 SPTB PKLR HBA2
30 hydrops fetalis, nonimmune 30.9 HBB HBA2
31 microcytic anemia 30.8 HBB HBA2 G6PD
32 plasmodium falciparum malaria 30.8 SLC4A1 HBB G6PD
33 hemoglobin h disease 30.7 HBB HBA2 G6PD AK1
34 alpha-thalassemia 30.7 HBB HBA2 G6PD
35 blood group incompatibility 30.6 SLC4A1 G6PD
36 hemolytic anemia, nonspherocytic, due to hexokinase deficiency 12.8
37 uridine 5-prime monophosphate hydrolase deficiency, hemolytic anemia due to 12.8
38 gamma-glutamylcysteine synthetase deficiency, hemolytic anemia due to 12.8
39 adenylate kinase deficiency, hemolytic anemia due to 12.8
40 glutathione synthetase deficiency of erythrocytes, hemolytic anemia due to 12.7
41 warm antibody hemolytic anemia 12.7
42 hemolytic anemia, congenital, x-linked 12.7
43 hemolytic anemia, nonspherocytic, due to glucose phosphate isomerase deficiency 12.7
44 renal tubular acidosis, distal, with hemolytic anemia 12.7
45 hemolytic anemia due to glutathione reductase deficiency 12.6
46 anemia, autoimmune hemolytic 12.6
47 hemolytic anemia, cd59-mediated, with or without immune-mediated polyneuropathy 12.6
48 systemic lupus erythematosus with hemolytic anemia 1 12.5
49 hemolytic anemia, lethal congenital nonspherocytic, with genital and other abnormalities 12.5
50 drug-induced autoimmune hemolytic anemia 12.4

Graphical network of the top 20 diseases related to Hemolytic Anemia:



Diseases related to Hemolytic Anemia

Symptoms & Phenotypes for Hemolytic Anemia

UMLS symptoms related to Hemolytic Anemia:


icterus

GenomeRNAi Phenotypes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

26 (show all 11)
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability GR00107-A-1 9.6 AK1
2 Decreased viability GR00221-A-1 9.6 PKLR
3 Decreased viability GR00221-A-2 9.6 PKLR
4 Decreased viability GR00221-A-4 9.6 PKLR
5 Decreased viability GR00240-S-1 9.6 ALDOA CD59
6 Decreased viability GR00249-S 9.6 ALDOA G6PD GPI PIEZO1 PKLR
7 Decreased viability GR00301-A 9.6 PKLR
8 Decreased viability GR00342-S-3 9.6 PKLR
9 Decreased viability GR00386-A-1 9.6 G6PD PIEZO1 SPTA1
10 Decreased viability GR00402-S-2 9.6 EPB42 G6PD SPTB
11 Decreased simian virus 40 (SV40) infection GR00356-A-2 8.65 PGK1

MGI Mouse Phenotypes related to Hemolytic Anemia:

45
# Description MGI Source Accession Score Top Affiliating Genes
1 hematopoietic system MP:0005397 10 ADAMTS13 ALDOA CD59 EPB42 G6PD GPI
2 homeostasis/metabolism MP:0005376 9.83 ADAMTS13 AK1 CD59 EPB42 G6PD GCLC
3 mortality/aging MP:0010768 9.44 ADAMTS13 ALDOA CD59 G6PD GCLC GPI

Drugs & Therapeutics for Hemolytic Anemia

PubMed Health treatment related to Hemolytic Anemia: 62

Treatments for hemolytic anemia include blood transfusions , medicines, plasmapheresis (PLAZ-meh-feh-RE-sis), surgery , blood and marrow stem cell transplants , and lifestyle changes. People who have mild hemolytic anemia may not need treatment , as long as the condition doesn't worsen. People who have severe hemolytic anemia usually need ongoing treatment. Severe hemolytic anemia can be fatal if it's not properly treated.

Drugs for Hemolytic Anemia (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 201)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Ribavirin Approved Phase 4 36791-04-5 37542
2
Peginterferon alfa-2a Approved, Investigational Phase 4 198153-51-4 5360545
3
Lumefantrine Approved Phase 4 82186-77-4 6437380
4
Artemether Approved Phase 4 71963-77-4 68911 9796294 119380
5
Nitric Oxide Approved Phase 4 10102-43-9 145068
6
Cefpirome Approved Phase 4 84957-29-9 5479539
7
Moxifloxacin Approved, Investigational Phase 4 354812-41-2, 151096-09-2 152946
8
Prilocaine Approved Phase 4 721-50-6 4906
9
Epinephrine Approved, Vet_approved Phase 4 51-43-4 5816
10
Mannitol Approved, Investigational Phase 4 69-65-8 6251 453
11
Racepinephrine Approved Phase 4 329-65-7 838
12
Mycophenolic acid Approved Phase 4 24280-93-1 446541
13
Azathioprine Approved Phase 4 446-86-6 2265
14
Ritonavir Approved, Investigational Phase 4 155213-67-5 392622
15
Tacrolimus Approved, Investigational Phase 4 104987-11-3 445643 439492 6473866
16
Metformin Approved Phase 4 657-24-9 14219 4091
17
Desogestrel Approved Phase 4 54024-22-5 40973
18
Etonogestrel Approved, Investigational Phase 4 54048-10-1 40976 6917715
19
Sotalol Approved Phase 4 3930-20-9, 959-24-0 5253
20
Bilirubin Phase 4 69853-43-6, 635-65-4 21252250 5280352
21 Immunoglobulins Phase 4
22 Antibodies Phase 4
23 Immunoglobulins, Intravenous Phase 4
24 Antirheumatic Agents Phase 4
25 Interferon-alpha Phase 4
26 interferons Phase 4
27 Artemether, Lumefantrine Drug Combination Phase 4
28 Interferon alpha-2 Phase 4
29 Rho(D) Immune Globulin Phase 4
30 gamma-Globulins Phase 4
31 Norgestimate, ethinyl estradiol drug combination Phase 4
32 Epinephryl borate Phase 4
33 diuretics Phase 4
34 Elbasvir-grazoprevir drug combination Phase 4
35 MK-5172 Phase 4
36 Antitubercular Agents Phase 4
37 Calcineurin Inhibitors Phase 4
38 Iron Chelating Agents Phase 4
39 Liver Extracts Phase 4
40 Hypoglycemic Agents Phase 4
41 Progestins Phase 4
42 Contraceptive Agents Phase 4
43
Ethylene Phase 4 74-85-1 6325
44 Neurotransmitter Agents Phase 4
45 Adrenergic Agents Phase 4
46 Sympatholytics Phase 4
47 Sodium Channel Blockers Phase 4
48 Adrenergic Antagonists Phase 4
49 Anti-Arrhythmia Agents Phase 4
50 Adrenergic beta-Antagonists Phase 4

Interventional clinical trials:

(show top 50) (show all 159)
# Name Status NCT ID Phase Drugs
1 Investigation of Signal Pathway Induced by Colla Corri Asini Regulating Globin Level in Beta Thalassemia Patients With Pregnancy Anemia Unknown status NCT03392298 Phase 4 Colla corii asini
2 A Multicenter Study to Evaluate the Efficacy of Yinzhihuang Oral Liquid on Indirect Bilirubin of Neonates With Glucose-6-phosphate Dehydrogenase Deficiency Unknown status NCT02594904 Phase 4 Yinzhihuang Oral Liquid
3 Low Dose Peginterferon and Ribavirin Therapy for Patients With Chronic Hepatitis C Infected With Genotype 2 or 3 Completed NCT00056862 Phase 4 Peginterferon alfa-2a;Peginterferon alfa-2a;Ribavirin
4 Efficacy and Safety of a Single Low-dose Primaquine Added to Standard Artemether-lumefantrine Treatment for the Clearance of Plasmodium Falciparum Gametocytes. Completed NCT02090036 Phase 4 Primaquine (For artemether-lumefantrine+primaquine arm);Placebo (For artemether-lumefantrine arm)
5 Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Versus Pegylated Interferon Alfa-2a Alone for Treatment-naïve Hemodialysis Patients With Chronic Hepatitis C Completed NCT00491244 Phase 4 Peginterferon alfa-2a and ribavirin;Peginterferon alfa-2a
6 Retreatment of Dialysis Patients With Chronic Hepatitis C With Pegylated Interferon Alfa-2a Plus Low Dose Ribavirin Who Fail Interferon Alfa or Pegylated Interferon Alfa Monotherapy - a Pilot Study Completed NCT00491179 Phase 4 Pegylated interferon alfa-2a and ribavirin;Pegylated interferon alfa-2a and ribavirin
7 A Pilot Study in Comparing the Efficacy and Safety of Peginterferon Alfa-2a and Interferon Alfa-2a in Treating Patients With End Stage Renal Disease and Chronic Hepatitis C Completed NCT00172809 Phase 4 Peginterferon alfa-2a;Interferon alfa-2a
8 Combination of Pegylated Interferon and Ribavirin as Therapy for Patients With Chronic Hepatitis C With and Without Renal Disease Completed NCT00028093 Phase 4 Peginterferon alfa-2a with Ribavirin;Peginterferon alfa-2a
9 Long-Term Therapy With Ribavirin for Chronic Hepatitis C Completed NCT00001854 Phase 4 Ribavirin
10 Plasma and Abscess Fluid Pharmacokinetics of Cefpirome and Moxifloxacin After Single and Multiple Dose Administration Completed NCT00280514 Phase 4 cefpirome and moxifloxacin administration
11 Phase 4 Study of Use of High-dose Intravenous Immune Globulin for Prevent Hyperbilirubinemia Due Rh Hemolytic Disease in Newborns Infants Completed NCT00288600 Phase 4 Intravenous Immunoglobulin;Normal saline solution
12 Evaluation of Ureteral Patency in the Post-indigo Carmine Era Completed NCT02677623 Phase 4 Pyridium;Sodium Fluorescein;Mannitol
13 Elbasvir/Grazoprevir for Treatment-naive and Treatment-experienced Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT03420300 Phase 4 EBR/GZR
14 A Randomized, Prospective, Multicenter Trial to Compare the Effect on Chronic Allograft Nephropathy Prevention of Mycophenolate Mofetil Versus Azathioprine as the Sole Immunosuppressive Therapy for Kidney Transplant Recipients Completed NCT00494741 Phase 4 mycophenolate mofetil;azathioprine
15 Paritaprevir/Ritonavir/Ombitasvir Plus Dasabuvir for Treatment-Naive and Treatment-Experienced Non-Cirrhotic Patients With Hepatitis C Virus Genotype 1b Receiving Hemodialysis Completed NCT02874066 Phase 4 PTV/r/OBV/DSV
16 Tacrolimus Treatment for Refractory Autoimmune Cytopenia Recruiting NCT03918265 Phase 4 Tacrolimus
17 A Multi-center Randomized, Double-blind, Placebo-controlled Study of Colla Corii Asini for the Treatment of Anemia in Pregnant Women With Thalassemia(Presenting the Syndrome of Blood Deficiency) Recruiting NCT03374111 Phase 4 Colla corii asini;a Simulate Agent of Colla corii asini granule
18 The Potential Hepatoprotective Effect of Metformin in Patients With Beta Thalasemia Major Recruiting NCT02984475 Phase 4 Metformin
19 Use of Etonogestrel-releasing Contraceptive Implant in Women With Sickle Cell Disease Active, not recruiting NCT02594462 Phase 4 etonogestrel-releasing implant contraceptive
20 A Prospective, Multi-Center, Randomized, Open Label Trial to Determine if a Common Atrial Fibrillation Risk Locus Modulates Differential Response to Antiarrhythmic Drugs Not yet recruiting NCT02347111 Phase 4 Flecainide;Sotalol
21 Anti-CD20 Antibody Rituximab in Addition to Prednisolone in Treatment of Warm Antibody Related Autoimmune Hemolytic Anemia. A Randomised Danish Multicenter Trial. Completed NCT01134432 Phase 3 prednisolone + mabthera;Prednisolone
22 Low Doses of Alemtuzumab and Rituximab in the Treatment of Refractory Autoimmune Cytopenias Completed NCT00749112 Phase 2, Phase 3 Alemtuzumab, Rituximab
23 Rituximab in Adult's Warm Auto-Immune Hemolytic Anemia : a Phase III, Double-bind, Randomised Placebo-controlled Trial Completed NCT01181154 Phase 3 rituximab (Mabthera®);Placebo
24 Combination of Alpha Interferon With Long Term Ribavirin Therapy for Patients With Chronic Hepatitis C Completed NCT00001729 Phase 3 Ribavirin
25 Minimally Invasive Management of Rh Alloimmunization: Can Amniotic Fluid DeltaOD450 Measurements Be Replaced by Doppler Studies? Completed NCT00295516 Phase 3
26 An Open-label, Randomized Pilot Study to Compare the Effectiveness of Peginterferon-alfa-2b Plus Ribavirin to Peginterferon-alfa-2b Plus Epoetin-alfa and Two Doses of Ribavirin in the Treatment of Chronic Hepatitis C Virus Infection Completed NCT00248339 Phase 3 Peginterferon-alpha-2b (PEG-Intron);Ribavirin;Epoetin-alpha (Procrit)
27 Single-agent Rituximab as Maintenance Treatment Versus Observation After Combined Induction Immunochemotherapy With Fludarabine, Cyclophosphamide and Rituximab in Patients Older Than 65 Years With Previously Untreated Chronic Lymphocytic Leukemia: a Phase III Trial of FILO Completed NCT00645606 Phase 3
28 Early Treatment With the Monoclonal C5 Antibody Eculizumab in Pediatric Patients Affected by Shiga-toxin Related Hemolytic and Uremic Syndrome: A Phase III Prospective Randomized Controlled Therapeutic Trial Versus Placebo Completed NCT02205541 Phase 3 Eculizumab;Placebo
29 A Phase 3, Multi-Center, Randomized, Double-Blind, Placebo-Controlled, Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Recruiting NCT03764618 Phase 3 Fostamatinib disodium;Placebo
30 An Open-Label, Multicenter, Extension Study of AG-348 in Adult Subjects With Pyruvate Kinase Deficiency Previously Enrolled in AG-348 Studies Recruiting NCT03853798 Phase 3 AG-348
31 Sickle Cell Disease and CardiovAscular Risk - Red Cell Exchange Trial (SCD-CARRE) Recruiting NCT04084080 Phase 3
32 A Double-blind, Placebo-controlled, Adaptive, Phase 2/3 Study to Evaluate the Pharmacokinetics, Safety, and Efficacy of INM004 in Pediatric Patients With Shiga Toxin-positive Bloody Diarrhea for Prevention of Hemolytic Uremic Syndrome Recruiting NCT04132375 Phase 2, Phase 3 INM004;Placebo
33 A Phase 3 Open Label Extension Study of Fostamatinib Disodium in the Treatment of Warm Antibody Autoimmune Hemolytic Anemia Active, not recruiting NCT04138927 Phase 3 Fostamatinib disodium
34 An Open-Label Study To Evaluate the Efficacy and Safety of AG-348 in Regularly Transfused Adult Subjects With Pyruvate Kinase (PK) Deficiency Active, not recruiting NCT03559699 Phase 3 AG-348
35 A Phase 3, Randomized, Double-blind, Placebo-controlled Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Without a Recent History of Blood Transfusion Active, not recruiting NCT03347422 Phase 3 Sutimlimab;Placebo
36 A Phase 3, Pivotal, Open-label, Multicenter Study to Assess the Efficacy and Safety of Sutimlimab in Patients With Primary Cold Agglutinin Disease Who Have a Recent History of Blood Transfusion Active, not recruiting NCT03347396 Phase 3 Sutimlimab
37 A Phase 3, Randomized, Double-Blind, Placebo-Controlled Study to Evaluate the Efficacy and Safety of AG-348 in Not Regularly Transfused Adult Subjects With Pyruvate Kinase Deficiency Active, not recruiting NCT03548220 Phase 3 AG-348;Placebo
38 An Open Label Extension Study of Voxelotor (GBT440) Administered Orally to Participants With Sickle Cell Disease Who Have Participated in Voxelotor Clinical Trials Active, not recruiting NCT03573882 Phase 3 Voxelotor
39 Randomized Trial: Maternal Vitamin D Supplementation to Prevent Childhood Asthma (VDAART) Active, not recruiting NCT00920621 Phase 3
40 Sirolimus Combined With All Trans Retinoic Acid for the Treatment of Auto-Immune Anemia Not yet recruiting NCT04324411 Phase 2, Phase 3 sirolimus and ATRA
41 Clinical Trial Evaluating Safety and Efficacy of Hydroxychloroquine and Nitazoxanide Combination as Adjuvant Therapy in Covid-19 Newly Diagnosed Egyptian Patients: A Tanta University Hope Not yet recruiting NCT04361318 Phase 2, Phase 3
42 Efficacy and Safety of M281 in Adults With Warm Autoimmune Hemolytic Anemia: A Multicenter, Randomized, Double-blind, Placebo-controlled Study Suspended NCT04119050 Phase 2, Phase 3 M281;Placebo
43 High-dose Versus Standard-dose Weight-based Ribavirin in Combination With Peginterferon Alfa-2a for Patients Infected With Hepatitis C Virus Genotype 1 or 4 Terminated NCT00662220 Phase 3 ribavirin;ribavirin
44 Efficacy and Safety of Levamisole Combined With Standard Prednisolone in Warm Antibody Autoimmune Hemolytic Anemia. Unknown status NCT01579110 Phase 2 levamisole;Prednisone
45 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Subclinical Paroxysmal Nocturnal Hemoglobinuria and PNH in the Setting of Another Bone Marrow Failure Syndromes(PNH-2013) Unknown status NCT01760096 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
46 Phase II Study of the Levamisole Combined With Cyclosporine A in Patients With Classic Paroxysmal Nocturnal Hemoglobinuria Unknown status NCT01642979 Phase 2 Levamisole+cyclosporin A+Glucocorticoids;cyclosporin A+Glucocorticoids;Glucocorticoids
47 Phase II Randomized Double-Blind Placebo-Controlled Trial of the Omega-3 Fatty Acids Eicosapentaenoic (EPA) and Docosahexaenoic Acid (DHA) in Pediatric Sickle Cell Disease (SCD) Unknown status NCT01202812 Phase 2
48 Prevention of Chikungunya Infection in Neonates: Clinical Evaluation of Anti-CHIKV Hyperimmune Intravenous Immunoglobulins Unknown status NCT02230163 Phase 1, Phase 2
49 Phase II Study of High-Dose Cyclophosphamide in Patients With Severe Autoimmune Hematologic Disease Completed NCT00010387 Phase 2 cyclophosphamide;filgrastim
50 A Single-Arm Pilot Study With Low-Dose Rituximab Plus Standard Oral Prednisone In Idiopathic Autoimmune Hemolytic Anemia Completed NCT01345708 Phase 2 prednisone, low dose rituximab

Search NIH Clinical Center for Hemolytic Anemia

Inferred drug relations via UMLS 71 / NDF-RT 50 :


alpha-Tocopherol Acetate
d-alpha-Tocopheryl Acetate
dl-alpha tocopheryl acetate
Tocopherol Acetate
TOCOPHEROL,DL-ALPHA
Tocopherols
TOCOPHERYL ACID SUCCINATE
TOCOPHERYL ACID SUCCINATE,D-ALPHA
Vitamin E

Cell-based therapeutics:


LifeMap Discovery
Data from LifeMap, the Embryonic Development and Stem Cells Database
Read about Hemolytic Anemia cell therapies at LifeMap Discovery.

Cochrane evidence based reviews: anemia, hemolytic

Genetic Tests for Hemolytic Anemia

Genetic tests related to Hemolytic Anemia:

# Genetic test Affiliating Genes
1 Hemolytic Anemia 29

Anatomical Context for Hemolytic Anemia

MalaCards organs/tissues related to Hemolytic Anemia:

40
Testes, Liver, Bone, Bone Marrow, Heart, Kidney, Spleen

Publications for Hemolytic Anemia

Articles related to Hemolytic Anemia:

(show top 50) (show all 13199)
# Title Authors PMID Year
1
Hemoglobin Sendagi (beta 42 Phe----Val): a new unstable hemoglobin variant having an amino acid substitution at CD1 of the beta-chain. 61 6
3781864 1986
2
Hemoglobin Louisville (beta-42 (CD1) phe-leu): an unstable variant causing mild hemolytic anemia. 61 6
5096522 1971
3
Hb south Milwaukee [beta 105 (G7) Leu----Phe]: a newly-identified hemoglobin variant with high oxygen affinity. 6
2363414 1990
4
A new Spanish family with Hb Louisville. 6
2705488 1989
5
Haemoglobin Buccureşti 42(CD1) Phe-Leu, a cause of unstable haemoglobin haemolytic anaemia. 6
5133275 1971
6
Gastrointestinal and hepatic complications of sickle cell disease. 54 61
20215064 2010
7
Glucose-6-phosphate dehydrogenase and red cell pyruvate kinase deficiency in neonatal jaundice cases in egypt. 54 61
20426517 2010
8
Aseptic meningitis, hemolytic anemia, hepatitis, and orthostatic hypotension in a patient treated with trimethoprim-sulfamethoxazole. 61 54
20065266 2010
9
Rescue of pyruvate kinase deficiency in mice by gene therapy using the human isoenzyme. 61 54
19755962 2009
10
Positively selected G6PD-Mahidol mutation reduces Plasmodium vivax density in Southeast Asians. 61 54
20007901 2009
11
Adenosine deaminase-adenosine pathway in hemolysis-associated pulmonary hypertension. 61 54
19237250 2009
12
Early erythropoietin reduced the need for red blood cell transfusion in childhood hemolytic uremic syndrome: a randomized prospective pilot trial. 54 61
19085014 2009
13
Sickle cell anemia in northern Israel: screening and prevention. 61 54
19603597 2009
14
A hemolysis trigger in glucose-6-phosphate dehydrogenase enzyme deficiency. Vicia sativa (Vetch). 54 61
19198723 2009
15
A case of cold agglutinin disease in the course of treatment for polymyalgia rheumatica. 54 61
19340395 2009
16
Brucellosis triggering hemolytic anemia in glucose-6-phosphate dehydrogenase deficiency. 54 61
19494543 2009
17
Heme induces endothelial tissue factor expression: potential role in hemostatic activation in patients with hemolytic anemia. 54 61
18983524 2008
18
A novel G6PD mutation leading to chronic hemolytic anemia. 54 61
18677765 2008
19
Glucose-6-phosphate dehydrogenase deficiency associated stuttering priapism: report of a case. 61 54
18823322 2008
20
Hematological abnormalities in patients with distal renal tubular acidosis and hemoglobinopathies. 61 54
18266205 2008
21
Degradation of functional triose phosphate isomerase protein underlies sugarkill pathology. 61 54
18458110 2008
22
Complement factor H deficiency and posttransplantation glomerulonephritis with isolated C3 deposits. 61 54
18371543 2008
23
Crystal structure of a core domain of stomatin from Pyrococcus horikoshii Illustrates a novel trimeric and coiled-coil fold. 54 61
18182167 2008
24
Altered expression of PGK1 in a family with phosphoglycerate kinase deficiency. 61 54
17661373 2007
25
Restoration of the balanced alpha/beta-globin gene expression in beta654-thalassemia mice using combined RNAi and antisense RNA approach. 54 61
17716993 2007
26
Chronic non-spherocytic hemolytic anemia associated with severe neurological disease due to gamma-glutamylcysteine synthetase deficiency in a patient of Moroccan origin. 54 61
18024385 2007
27
Point mutations involved in red cell stomatocytosis convert the electroneutral anion exchanger 1 to a nonselective cation conductance. 54 61
17554061 2007
28
Seven different glucose-6-phosphate dehydrogenase variants including a new variant distributed in Lam Dong Province in southern Vietnam. 54 61
17726510 2007
29
Transgenic rescue of hemolytic anemia due to red blood cell pyruvate kinase deficiency. 54 61
17550844 2007
30
In vitro and in vivo expression of human erythrocyte pyruvate kinase in erythroid cells: a gene therapy approach. 61 54
17547515 2007
31
Cardiac hypertrophy in anion exchanger 1-null mutant mice with severe hemolytic anemia. 54 61
17056673 2007
32
Inborn errors in the metabolism of glutathione. 54 61
17397529 2007
33
Thrombotic microangiopathy in a sirolimus-treated renal transplant patient receiving gemcitabine for lung cancer. 61 54
17338432 2007
34
Glucose-6-phosphate dehydrogenase--from oxidative stress to cellular functions and degenerative diseases. 54 61
17623517 2007
35
Improved quantitative method for G6PD deficiency detection. 61 54
17385678 2007
36
Red cell glucose phosphate isomerase (GPI): a molecular study of three novel mutations associated with hereditary nonspherocytic hemolytic anemia. 54 61
17041899 2006
37
Monoclonal anti-double-stranded DNA antibodies cross-react with phosphoglycerate kinase 1 and inhibit the expression and production of IL-2 in activated Jurkat T cell line. 61 54
16857429 2006
38
Two new mutations of the P5'N-1 gene found in Italian patients with hereditary hemolytic anemia: the molecular basis of the red cell enzyme disorder. 61 54
16956825 2006
39
Haptoglobin levels are associated with haptoglobin genotype and alpha+ -Thalassemia in a malaria-endemic area. 61 54
16760505 2006
40
Reactivity of blood samples spotted onto filter papers in the WST-8 method for screening of G6PD deficiency. 61 54
16680190 2006
41
G6PD deficiency with hemolytic anemia due to a rare gene deletion--a report of the first case in Malaysia. 61 54
16753852 2006
42
Rh proteins: key structural and functional components of the red cell membrane. 54 61
15961204 2006
43
Hereditary erythrocyte pyrimidine 5'-nucleotidase deficiency: a biochemical, genetic and clinical overview. 54 61
16522554 2006
44
New insights into paroxysmal nocturnal hemoglobinuria. 61 54
17124035 2006
45
Complications related to dapsone use for Pneumocystis jirovecii pneumonia prophylaxis in solid organ transplant recipients. 54 61
16212642 2005
46
Hemolysis and methemoglobinemia secondary to rasburicase administration. 61 54
16204390 2005
47
An adult with acute poststreptococcal glomerulonephritis complicated by hemolytic uremic syndrome and nephrotic syndrome. 54 61
16183409 2005
48
Life-threatening nonspherocytic hemolytic anemia in a patient with a null mutation in the PKLR gene and no compensatory PKM gene expression. 54 61
15870173 2005
49
Two new glucose-6-phosphate dehydrogenase mutations causing chronic hemolysis. 61 54
16079115 2005
50
Glucose phosphate isomerase deficiency: enzymatic and familial characterization of Arg346His mutation. 54 61
15949716 2005

Variations for Hemolytic Anemia

ClinVar genetic disease variations for Hemolytic Anemia:

6 (show top 50) (show all 141) ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎ ‎‎
# Gene Name Type Significance ClinVarId dbSNP ID GRCh37 Pos GRCh38 Pos
1 SPTB NM_001355436.2(SPTB):c.5794_5798+6deldeletion Pathogenic 523359 rs1555367318 14:65237597-65237607 14:64770879-64770889
2 HBB NM_000518.5(HBB):c.127T>C (p.Phe43Leu)SNV Pathogenic 15251 rs33924146 11:5247995-5247995 11:5226765-5226765
3 HBB NM_000518.4(HBB):c.127T>G (p.Phe43Val)SNV Pathogenic 15347 rs33924146 11:5247995-5247995 11:5226765-5226765
4 PKLR NM_000298.6(PKLR):c.1291G>A (p.Ala431Thr)SNV Likely pathogenic 812888 1:155263113-155263113 1:155293322-155293322
5 SPTA1 NM_003126.4(SPTA1):c.4177C>T (p.Gln1393Ter)SNV Likely pathogenic 812889 1:158614995-158614995 1:158645205-158645205
6 SPTA1 NM_003126.4(SPTA1):c.2353C>T (p.Arg785Ter)SNV Likely pathogenic 812891 1:158632603-158632603 1:158662813-158662813
7 SLC4A1 NM_000342.4(SLC4A1):c.733G>A (p.Val245Met)SNV Conflicting interpretations of pathogenicity 854724 17:42336674-42336674 17:44259306-44259306
8 SLC4A1 NM_000342.4(SLC4A1):c.2193C>T (p.Ser731=)SNV Conflicting interpretations of pathogenicity 737923 17:42330604-42330604 17:44253236-44253236
9 SLC4A1 NM_000342.4(SLC4A1):c.*5C>TSNV Conflicting interpretations of pathogenicity 891768 17:42327821-42327821 17:44250453-44250453
10 SLC4A1 NM_000342.4(SLC4A1):c.*1393A>TSNV Conflicting interpretations of pathogenicity 891315 17:42326433-42326433 17:44249065-44249065
11 SLC4A1 NM_000342.4(SLC4A1):c.486-10C>TSNV Conflicting interpretations of pathogenicity 892040 17:42337310-42337310 17:44259942-44259942
12 SLC4A1 NM_000342.4(SLC4A1):c.1151G>A (p.Arg384His)SNV Conflicting interpretations of pathogenicity 890178 17:42335485-42335485 17:44258117-44258117
13 SLC4A1 NM_000342.4(SLC4A1):c.826A>G (p.Ile276Val)SNV Conflicting interpretations of pathogenicity 891993 17:42336581-42336581 17:44259213-44259213
14 SLC4A1 NM_000342.4(SLC4A1):c.719C>T (p.Pro240Leu)SNV Conflicting interpretations of pathogenicity 889578 17:42336688-42336688 17:44259320-44259320
15 SLC4A1 NM_000342.4(SLC4A1):c.706T>G (p.Phe236Val)SNV Conflicting interpretations of pathogenicity 889579 17:42336701-42336701 17:44259333-44259333
16 SLC4A1 NM_000342.4(SLC4A1):c.1937G>A (p.Arg646Gln)SNV Conflicting interpretations of pathogenicity 17782 rs121912757 17:42331984-42331984 17:44254616-44254616
17 SLC4A1 NM_000342.4(SLC4A1):c.2603C>T (p.Pro868Leu)SNV Conflicting interpretations of pathogenicity 17783 rs121912759 17:42328579-42328579 17:44251211-44251211
18 SLC4A1 NM_000342.4(SLC4A1):c.2701C>T (p.Arg901Trp)SNV Conflicting interpretations of pathogenicity 64423 rs201265160 17:42327861-42327861 17:44250493-44250493
19 SPTA1 NM_003126.4(SPTA1):c.6549-12G>ASNV Conflicting interpretations of pathogenicity 258955 rs857716 1:158587390-158587390 1:158617600-158617600
20 SPTA1 NM_003126.4(SPTA1):c.6531-12C>TSNV Conflicting interpretations of pathogenicity 258954 rs28525570 1:158587858-158587858 1:158618068-158618068
21 SLC4A1 NM_000342.4(SLC4A1):c.2625G>A (p.Pro875=)SNV Conflicting interpretations of pathogenicity 890020 17:42328557-42328557 17:44251189-44251189
22 SLC4A1 NM_000342.4(SLC4A1):c.2547G>A (p.Val849=)SNV Conflicting interpretations of pathogenicity 891836 17:42328635-42328635 17:44251267-44251267
23 SLC4A1 NM_000342.4(SLC4A1):c.2401A>C (p.Ser801Arg)SNV Conflicting interpretations of pathogenicity 889392 17:42328867-42328867 17:44251499-44251499
24 SLC4A1 NM_000342.4(SLC4A1):c.1971C>T (p.Ser657=)SNV Conflicting interpretations of pathogenicity 890659 17:42331950-42331950 17:44254582-44254582
25 SLC4A1 NM_000342.4(SLC4A1):c.1928C>T (p.Ser643Phe)SNV Conflicting interpretations of pathogenicity 889445 17:42331993-42331993 17:44254625-44254625
26 SLC4A1 NM_000342.4(SLC4A1):c.1671G>A (p.Val557=)SNV Conflicting interpretations of pathogenicity 890131 17:42333170-42333170 17:44255802-44255802
27 SLC4A1 NM_000342.4(SLC4A1):c.672A>G (p.Ser224=)SNV Conflicting interpretations of pathogenicity 890231 17:42336887-42336887 17:44259519-44259519
28 SLC4A1 NM_000342.4(SLC4A1):c.615T>C (p.Asp205=)SNV Conflicting interpretations of pathogenicity 890797 17:42336944-42336944 17:44259576-44259576
29 SLC4A1 NM_000342.4(SLC4A1):c.567C>G (p.Leu189=)SNV Conflicting interpretations of pathogenicity 890798 17:42337219-42337219 17:44259851-44259851
30 SLC4A1 NM_000342.3(SLC4A1):c.118G>A (p.Glu40Lys)SNV Conflicting interpretations of pathogenicity 17756 rs45562031 17:42338993-42338993 17:44261625-44261625
31 SLC4A1 NM_000342.4(SLC4A1):c.1972G>A (p.Glu658Lys)SNV Conflicting interpretations of pathogenicity 17759 rs75731670 17:42331949-42331949 17:44254581-44254581
32 SLC4A1 NM_000342.4(SLC4A1):c.539G>A (p.Arg180His)SNV Conflicting interpretations of pathogenicity 255914 rs147390654 17:42337247-42337247 17:44259879-44259879
33 SLC4A1 NM_000342.4(SLC4A1):c.173A>G (p.Tyr58Cys)SNV Conflicting interpretations of pathogenicity 323520 rs368863744 17:42338179-42338179 17:44260811-44260811
34 SLC4A1 NM_000342.4(SLC4A1):c.2630T>C (p.Ile877Thr)SNV Conflicting interpretations of pathogenicity 323501 rs765911147 17:42328552-42328552 17:44251184-44251184
35 SLC4A1 NM_000342.4(SLC4A1):c.2208C>T (p.Asn736=)SNV Conflicting interpretations of pathogenicity 323505 rs766674440 17:42330589-42330589 17:44253221-44253221
36 SLC4A1 NM_000342.4(SLC4A1):c.884G>A (p.Arg295His)SNV Conflicting interpretations of pathogenicity 323512 rs140424071 17:42335984-42335984 17:44258616-44258616
37 SLC4A1 NM_000342.4(SLC4A1):c.202G>A (p.Glu68Lys)SNV Conflicting interpretations of pathogenicity 323519 rs13306787 17:42338150-42338150 17:44260782-44260782
38 SLC4A1 NM_000342.4(SLC4A1):c.*351G>TSNV Conflicting interpretations of pathogenicity 323495 rs138242019 17:42327475-42327475 17:44250107-44250107
39 SLC4A1 NM_000342.4(SLC4A1):c.457C>A (p.Leu153Met)SNV Conflicting interpretations of pathogenicity 323516 rs145041032 17:42337800-42337800 17:44260432-44260432
40 SLC4A1 NM_000342.4(SLC4A1):c.-65C>ASNV Uncertain significance 323523 rs886053001 17:42340299-42340299 17:44262931-44262931
41 SLC4A1 NM_000342.4(SLC4A1):c.2482-9C>TSNV Uncertain significance 323502 rs886052995 17:42328709-42328709 17:44251341-44251341
42 SLC4A1 NM_000342.4(SLC4A1):c.2243G>A (p.Gly748Glu)SNV Uncertain significance 323503 rs886052996 17:42330554-42330554 17:44253186-44253186
43 SLC4A1 NM_000342.4(SLC4A1):c.*1596A>CSNV Uncertain significance 323480 rs886052990 17:42326230-42326230 17:44248862-44248862
44 SLC4A1 NM_000342.4(SLC4A1):c.*1316C>TSNV Uncertain significance 323482 rs886052991 17:42326510-42326510 17:44249142-44249142
45 SLC4A1 NM_000342.4(SLC4A1):c.876+14G>ASNV Uncertain significance 323513 rs571092411 17:42336517-42336517 17:44259149-44259149
46 SLC4A1 NM_000342.4(SLC4A1):c.697C>G (p.Arg233Gly)SNV Uncertain significance 323514 rs779054292 17:42336710-42336710 17:44259342-44259342
47 SLC4A1 NM_000342.4(SLC4A1):c.1431+15G>TSNV Uncertain significance 323508 rs886052999 17:42335012-42335012 17:44257644-44257644
48 G6PD NM_001360016.2(G6PD):c.1096A>G (p.Lys366Glu)SNV Uncertain significance 374205 rs1057518975 X:153760973-153760973 X:154532758-154532758
49 SLC4A1 NM_000342.4(SLC4A1):c.*1608dupduplication Uncertain significance 323477 rs57466226 17:42326217-42326218 17:44248849-44248850
50 SLC4A1 NM_000342.4(SLC4A1):c.*1273G>TSNV Uncertain significance 323484 rs769140134 17:42326553-42326553 17:44249185-44249185

Expression for Hemolytic Anemia

Search GEO for disease gene expression data for Hemolytic Anemia.

Pathways for Hemolytic Anemia

Pathways related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 13)
# Super pathways Score Top Affiliating Genes
1
Show member pathways
13.82 SLC4A1 RHAG PKLR PGK1 NT5C3A HK1
2
Show member pathways
12.63 PKLR PGK1 HK1 GPI G6PD ALDOA
3
Show member pathways
12.41 PKLR PGK1 HK1 GPI ALDOA
4 12.31 HK1 HBB G6PD ALDOA
5
Show member pathways
11.76 PKLR PGK1 HK1 GPI G6PD ALDOA
6 11.72 PGK1 HK1 ALDOA
7
Show member pathways
11.68 PKLR PGK1 HK1 ALDOA
8 11.47 PGK1 HK1 ALDOA
9
Show member pathways
11.43 GPI G6PD ALDOA
10
Show member pathways
11 SLC4A1 RHAG HBB HBA2
11 10.61 PKLR PGK1
12
Show member pathways
10.39 HK1 GPI G6PD
13 10.13 PGK1 HK1 GPI G6PD

GO Terms for Hemolytic Anemia

Cellular components related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 11)
# Name GO ID Score Top Affiliating Genes
1 cytosol GO:0005829 10 SPTB SPTA1 PKLR PGK1 NT5C3A HK1
2 ficolin-1-rich granule lumen GO:1904813 9.67 HBB GPI ALDOA
3 cytoplasmic side of plasma membrane GO:0009898 9.5 SPTA1 SLC4A1 G6PD
4 endocytic vesicle lumen GO:0071682 9.48 HBB HBA2
5 hemoglobin complex GO:0005833 9.46 HBB HBA2
6 haptoglobin-hemoglobin complex GO:0031838 9.43 HBB HBA2
7 spectrin GO:0008091 9.4 SPTB SPTA1
8 spectrin-associated cytoskeleton GO:0014731 9.37 SPTB SPTA1
9 extracellular exosome GO:0070062 9.36 SLC4A1 PKLR PGK1 HBB HBA2 GSS
10 intrinsic component of the cytoplasmic side of the plasma membrane GO:0031235 9.26 SPTB SPTA1
11 cortical cytoskeleton GO:0030863 9.13 SPTA1 SLC4A1 EPB42

Biological processes related to Hemolytic Anemia according to GeneCards Suite gene sharing:

(show all 15)
# Name GO ID Score Top Affiliating Genes
1 carbohydrate metabolic process GO:0005975 9.76 PKLR HK1 GPI G6PD
2 blood coagulation GO:0007596 9.73 SLC4A1 HBB CD59 ADAMTS13
3 erythrocyte development GO:0048821 9.55 SLC4A1 RHAG
4 actin filament capping GO:0051693 9.54 SPTB SPTA1
5 gluconeogenesis GO:0006094 9.54 PGK1 GPI ALDOA
6 oxygen transport GO:0015671 9.52 HBB HBA2
7 erythrocyte maturation GO:0043249 9.51 G6PD EPB42
8 response to cadmium ion GO:0046686 9.5 GSS GPI GCLC
9 glutathione biosynthetic process GO:0006750 9.49 GSS GCLC
10 response to xenobiotic stimulus GO:0009410 9.48 GSS GCLC
11 bicarbonate transport GO:0015701 9.46 SLC4A1 RHAG HBB HBA2
12 glucose 6-phosphate metabolic process GO:0051156 9.43 HK1 GPI G6PD
13 cellular ion homeostasis GO:0006873 9.4 SLC4A1 RHAG
14 glycolytic process GO:0006096 9.35 PKLR PGK1 HK1 GPI ALDOA
15 canonical glycolysis GO:0061621 9.02 PKLR PGK1 HK1 GPI ALDOA

Molecular functions related to Hemolytic Anemia according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 ATP binding GO:0005524 10 PKLR PGK1 HK1 GSS GCLC EPB42
2 structural constituent of cytoskeleton GO:0005200 9.61 SPTB SPTA1 EPB42
3 magnesium ion binding GO:0000287 9.46 PKLR NT5C3A GSS GCLC
4 oxygen carrier activity GO:0005344 9.4 HBB HBA2
5 organic acid binding GO:0043177 9.37 HBB HBA2
6 glucose binding GO:0005536 9.32 HK1 G6PD
7 haptoglobin binding GO:0031720 9.26 HBB HBA2
8 hemoglobin binding GO:0030492 8.96 SLC4A1 HBB
9 ankyrin binding GO:0030506 8.8 SPTB SLC4A1 RHAG

Sources for Hemolytic Anemia

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
43 MeSH
44 MESH via Orphanet
45 MGI
48 NCI
49 NCIt
50 NDF-RT
53 NINDS
54 Novoseek
56 OMIM
57 OMIM via Orphanet
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 TGDB
70 Tocris
71 UMLS
72 UMLS via Orphanet
Content
Loading form....